The European healthcare system is rapidly evolving, with biosimilars playing a pivotal role in expanding access to biologic therapies at reduced costs. As chronic disease burden rises, so does the need for affordable yet effective treatment options. According to Expert Market Research, the Europe biosimilar market reached a valuation of USD 10.13 billion in 2024 and is projected to grow at a CAGR of 12.80% during 2025–2034, reaching USD 33.78 billion by 2034.
Europe Biosimilar Market Size
The biosimilar landscape in Europe is maturing, supported by favorable regulatory pathways, patent expirations of key biologics, and increasing physician and patient acceptance. With over 90 approved biosimilars by the European Medicines Agency (EMA), Europe remains a global frontrunner in biosimilar adoption.
This robust ecosystem has positioned biosimilars as a critical component of chronic disease management, especially for oncology, autoimmune disorders, and diabetes, contributing significantly to cost containment in national health budgets.
Europe Biosimilar Market Share
The European biosimilar market is dominated by a few major pharmaceutical companies with strong manufacturing capabilities and established portfolios. Novartis (through Sandoz), Amgen, and Pfizer are among the leading players in terms of market penetration and brand recognition.
In terms of geographic distribution:
Germany and the United Kingdom have emerged as key biosimilar markets due to supportive pricing policies and quicker substitution pathways.
France and Italy are witnessing gradual uptake with expanding hospital use and tender-based procurement systems.
Therapeutic areas such as oncology, autoimmune diseases, and blood disorders account for the largest share of biosimilar consumption across Europe.
Europe Biosimilar Market Growth & Trends
Several macro and micro trends are driving the biosimilar market’s expansion in Europe:
Patent Expirations: The expiry of blockbuster biologic drugs like Humira, Herceptin, and Remicade has opened doors for biosimilar competition.
Cost Pressure on Healthcare Systems: With aging populations and rising chronic conditions, biosimilars provide governments and payers with sustainable, cost-effective alternatives to expensive biologics.
Technological Advancements: Enhanced biomanufacturing capabilities, improved delivery systems, and pharmaceutical cleanroom technology are enabling higher production quality, sterility, and scalability in biosimilar development.
Regulatory Support: The EMA has streamlined approval procedures, setting a global benchmark in biosimilar assessment and pharmacovigilance.
Growing Acceptance: Physician confidence in the clinical efficacy and safety of biosimilars continues to rise, helped by real-world evidence and interchangeable designations.
For more background, you can refer to the Wikipedia page on biosimilars.
Europe Biosimilar Market Case Studies & News
In 2024, Celltrion and Samsung Bioepis launched new biosimilars in the EU market for oncology and immunology, following swift EMA approvals.
Pfizer expanded its biosimilar product line across Western Europe, with growing uptake in hospital-based procurement systems.
Sanofi announced partnerships with contract manufacturing organizations (CMOs) in Eastern Europe to support regional biosimilar supply.
These developments highlight the industry’s shift toward collaborative manufacturing, decentralization, and rapid product introduction.
Europe Biosimilar Market Analysis
The competitive landscape is shaped by a mix of originator pharma companies, generic drug manufacturers, and biotech firms. Pricing dynamics are particularly sensitive, with many biosimilars launched at 20% to 30% lower prices than reference products.
Key strategic imperatives include:
Scalability through in-house and contract manufacturing
Securing hospital tenders in high-volume EU countries
Investing in cleanroom facilities to meet strict quality and sterility requirements
Cleanroom technology has become vital in biosimilar production to maintain compliance with EMA’s rigorous standards, especially in areas like aseptic filling, bioprocessing, and sterile packaging.
Europe Biosimilar Market Segmentation
By Molecule:
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Others
These molecules dominate due to their clinical importance in managing chronic illnesses and their early patent expirations.
By Manufacturing Type:
In-house Manufacturing – Favored by large pharma for quality control and supply chain efficiency.
Contract Manufacturing – Growing among mid-sized companies to reduce CapEx and leverage specialized expertise.
By Indication:
Auto-Immune Diseases
Blood Disorders
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others
Oncology and autoimmune indications remain top revenue generators due to high treatment costs and extended therapy durations.
By Country:
United Kingdom
Germany
France
Italy
Others
Germany continues to lead in biosimilar usage volume, while other nations are adjusting reimbursement models to encourage broader adoption.
Europe Biosimilar Market Key Players
Leading pharmaceutical and biotechnology companies operating in the European biosimilar market include:
Pfizer, Inc.
Celltrion Inc.
Novartis AG
Amgen Inc.
Eli Lilly and Company
Samsung Bioepis
Sanofi SA
Dr. Reddy’s Laboratories Ltd.
Boehringer Ingelheim
These companies are investing heavily in pharmaceutical cleanroom technology to ensure compliance, especially in biologics manufacturing, which requires stringent contamination controls.
Explore More Reports
Electronic Health Records (EHR) Market
Implantable Medical Devices Market
Allergic Rhinitis Epidemiology Forecast
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
